Immunogenicity of Vero Cell Culture-derived Japanese Encephalitis Vaccine in Pediatric and Young Hematopoietic Stem Cell Transplantation Recipients.
Adolescent
Adult
Animals
Antibodies, Neutralizing
Antibodies, Viral
/ blood
Child
Child, Preschool
Chlorocebus aethiops
Encephalitis Virus, Japanese
/ immunology
Encephalitis, Japanese
/ prevention & control
Female
Hematopoietic Stem Cell Transplantation
Humans
Immunization, Secondary
Infant
Japanese Encephalitis Vaccines
/ immunology
Male
Prospective Studies
Transplant Recipients
Vaccines, Inactivated
Vero Cells
Young Adult
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
pubmed:
12
1
2021
medline:
25
9
2021
entrez:
11
1
2021
Statut:
ppublish
Résumé
Children and young adults undergoing hematopoietic stem cell transplantation (HSCT) typically lose their immunity to vaccine-preventable diseases, including Japanese encephalitis (JE). Revaccination against JE in this population has not been well characterized. This prospective study evaluated the immunogenicity of inactivated Vero cell culture-derived JE vaccine in children and young adults (<25 years of age) who had completed HSCT >1 year prior. Each patient received inactivated Vero cell culture-derived JE vaccine at enrollment and 1 month after enrollment, as well as a booster dose 13 months after enrollment. Serum JE plaque reduction neutralization test and JE-specific T lymphocyte count assay were performed at baseline, 1 month after the second dose, on the day of the booster dose, and 1 month after the booster dose. Thirty-seven patients were enrolled. At baseline, 15 patients (40.5%) had plaque reduction neutralization titer >10, which is considered protective. Among 22 seronegative patients, 15 (68.2%) and 19 (86.4%) exhibited seroconversion after revaccination and booster dose, respectively. Median JE-specific T lymphocyte counts also increased. Twenty of 111 (18.0%) vaccination doses resulted in self-limiting side effects. The inactivated Vero cell culture-derived JE vaccine may be safe and effective for immunization against JE virus in children and young adults who have undergone HSCT.
Sections du résumé
BACKGROUND
Children and young adults undergoing hematopoietic stem cell transplantation (HSCT) typically lose their immunity to vaccine-preventable diseases, including Japanese encephalitis (JE). Revaccination against JE in this population has not been well characterized.
METHODS
This prospective study evaluated the immunogenicity of inactivated Vero cell culture-derived JE vaccine in children and young adults (<25 years of age) who had completed HSCT >1 year prior. Each patient received inactivated Vero cell culture-derived JE vaccine at enrollment and 1 month after enrollment, as well as a booster dose 13 months after enrollment. Serum JE plaque reduction neutralization test and JE-specific T lymphocyte count assay were performed at baseline, 1 month after the second dose, on the day of the booster dose, and 1 month after the booster dose.
RESULTS
Thirty-seven patients were enrolled. At baseline, 15 patients (40.5%) had plaque reduction neutralization titer >10, which is considered protective. Among 22 seronegative patients, 15 (68.2%) and 19 (86.4%) exhibited seroconversion after revaccination and booster dose, respectively. Median JE-specific T lymphocyte counts also increased. Twenty of 111 (18.0%) vaccination doses resulted in self-limiting side effects.
CONCLUSIONS
The inactivated Vero cell culture-derived JE vaccine may be safe and effective for immunization against JE virus in children and young adults who have undergone HSCT.
Identifiants
pubmed: 33427799
doi: 10.1097/INF.0000000000003007
pii: 00006454-202103000-00020
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Japanese Encephalitis Vaccines
0
Vaccines, Inactivated
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
264-268Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Campbell GL, Hills SL, Fischer M, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89:766–74, 774A.
Wang H, Liang G. Epidemiology of Japanese encephalitis: past, present, and future prospects. Ther Clin Risk Manag. 2015;11:435–448.
Bocchini JA, Rubin L, Fischer M, et al. Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013. MMWR Morb Mortal Wkly Rep. 2013;62:898–900.
World Health Organization. Japanese encephalitis vaccines: WHO position paper - February 2015. Wkly Epidemiol Record. 2015;90:69–87.
Centers for Disease Control and Prevention. Japanese encephalitis surveillance and immunization--Asia and the Western Pacific, 2012. MMWR Morb Mortal Wkly Rep. 2013;62:658–662.
Upreti SR, Janusz KB, Schluter WW, et al. Estimation of the impact of a Japanese encephalitis immunization program with live, attenuated SA 14-14-2 vaccine in Nepal. Am J Trop Med Hyg. 2013;88:464–468.
Fischer M, Lindsey N, Staples JE, et al.; Centers for Disease Control and Prevention (CDC). Japanese encephalitis vaccines: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2010;59(RR-1):1–27.
Chotpitayasunondh T, Sohn YM, Yoksan S, et al. Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand. J Med Assoc Thai. 2011;94(suppl 3):S195–S203.
Chanthavanich P, Limkittikul K, Sirivichayakul C, et al. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children. Hum Vaccin Immunother. 2018;14:900–905.
Muangchana C, Henprasertthae N, Nurach K, et al. Effectiveness of mouse brain-derived inactivated Japanese encephalitis vaccine in Thai National Immunization Program: a case-control study. Vaccine. 2012;30:361–367.
Okada K, Iwasa T, Namazue J, et al.; JE Vaccine Clinical Study Group. Safety and immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (Inactivated) (JEBIK(®)V) in children. Vaccine. 2012;30:5967–5972.
Ljungman P, Lewensohn-Fuchs I, Hammarström V, et al. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood. 1994;84:657–663.
Inaba H, Hartford CM, Pei D, et al. Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2012;156:109–117.
Pakakasama S, Wattanatitan S, Techasaensiri C, et al. Immunogenicity of a live-attenuated Japanese encephalitis vaccine in children and adolescents after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2014;49:1307–1309.
Rubin LG, Levin MJ, Ljungman P, et al.; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:e44–100.
Naqvi A, Fadoo Z, Alvi S. Vaccination guidelines for children with cancer and hematopoietic stem cell transplantation living in resource-poor countries. Pediatr Blood Cancer. 2010;54:3–7.
Yong-cheng L, Zhi-lun Z, Ying Z, et al. Safety evaluation of sequential schedules using freeze-dried Japanese encephalitis inactivated vaccine (Vero cell) and Japanese encephalitis attenuated live vaccine. Chinese Journal of Vaccines and Immunization. 2011;2:155–157.
Zun-dong Y, Hui-ming L, Jun G, et al. Safety analysis of the different immunization regimen for the Japanese encephalitis inactivated vaccine (Vero cell) and attenuated live vaccine. C hinese Journal of Vaccines and Immunization . 2011;3:195–200.
Apiwattanakul N, Hongeng S, Anurathapan U, et al. Viral-specific T-cell response in hemorrhagic cystitis after haploidentical donor stem cell transplantation. Transpl Infect Dis. 2017;19.